GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (FRA:ZA8) » Definitions » Deferred Policy Acquisition Costs

Zymeworks (FRA:ZA8) Deferred Policy Acquisition Costs


View and export this data going back to 2018. Start your Free Trial

What is Zymeworks Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Zymeworks (FRA:ZA8) Business Description

Industry
Traded in Other Exchanges
Address
108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.